|
1
|
Soen S, Fujiwara S, Takayanagi R, Kajimoto
K, Tsujimoto M, Kimura S, Sato M, Krege JH and Enomoto H:
Real-world effectiveness of daily teriparatide in Japanese patients
with osteoporosis at high risk for fracture: Final results from the
24-month Japan Fracture Observational Study (JFOS). Curr Med Res
Opin. 33:2049–2056. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Alkhiary YM, Gerstenfeld LC, Krall E,
Westmore M, Sato M, Mitlak BH and Einhorn TA: Enhancement of
experimental fracture-healing by systemic administration of
recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg
Am. 87:731–741. 2005.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Aspenberg P and Johansson T: Teriparatide
improves early callus formation in distal radial fractures. Acta
Orthop. 81:234–236. 2010.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Della Rocca GJ, Crist BD and Murtha YM:
Parathyroid hormone: Is there a role in fracture healing? J Orthop
Trauma. 24 (Suppl 1):S31–S35. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Hodsman AB, Bauer DC, Dempster DW, Dian L,
Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski
WP, et al: Parathyroid hormone and teriparatide for the treatment
of osteoporosis: A review of the evidence and suggested guidelines
for its use. Endocr Rev. 26:688–703. 2005.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Im GI and Lee SH: Effect of teriparatide
on healing of atypical femoral fractures: A systemic review. J Bone
Metab. 22:183–189. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Neer RM, Arnaud CD, Zanchetta JR, Prince
R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S,
Genant HK, et al: Effect of parathyroid hormone (1-34) on fractures
and bone mineral density in postmenopausal women with osteoporosis.
N Engl J Med. 344:1434–1441. 2001.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Puzas JE, Houck J and Bukata SV:
Accelerated fracture healing. J Am Acad Orthop Surg. 14:S145–S151.
2006.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Rowshan HH, Parham MA, Baur DA, McEntee
RD, Cauley E, Carriere DT, Wood JC, Demsar WJ and Pizarro JM:
Effect of intermittent systemic administration of recombinant
parathyroid hormone (1-34) on mandibular fracture healing in rats.
J Oral Maxillofac Surg. 68:260–267. 2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Subbiah V, Madsen VS, Raymond AK, Benjamin
RS and Ludwig JA: Of mice and men: Divergent risks of
teriparatide-induced osteosarcoma. Osteoporos Int. 21:1041–1045.
2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Harper KD, Krege JH, Marcus R and Mitlak
BH: Osteosarcoma and teriparatide? J Bone Miner Res.
22(334)2007.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Andrews EB, Gilsenan AW, Midkiff K,
Sherrill B, Wu Y, Mann BH and Masica D: The US postmarketing
surveillance study of adult osteosarcoma and teriparatide: Study
design and findings from the first 7 years. J Bone Miner Res.
27:2429–2437. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Vahle JL, Sato M, Long GG, Young JK,
Francis PC, Engelhardt JA, Westmore MS, Linda Y and Nold JB:
Skeletal changes in rats given daily subcutaneous injections of
recombinant human parathyroid hormone (1-34) for 2 years and
relevance to human safety. Toxicol Pathol. 30:312–321.
2002.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Watanabe A, Yoneyama S, Nakajima M, Sato
N, Takao-Kawabata R, Isogai Y, Sakurai-Tanikawa A, Higuchi K,
Shimoi A, Yamatoya H, et al: Osteosarcoma in Sprague-Dawley rats
after long-term treatment with teriparatide [human parathyroid
hormone (1-34)]. J Toxicol Sci. 37:617–629. 2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Vahle JL, Long GG, Sandusky G, Westmore M,
Ma YL and Sato M: Bone neoplasms in F344 rats given teriparatide
[rhPTH(1-34)] are dependent on duration of treatment and dose.
Toxicol Pathol. 32:426–438. 2004.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gilsenan A, Harding A, Kellier-Steele N,
Harris D, Midkiff K and Andrews E: The Forteo Patient Registry
linkage to multiple state cancer registries: Study design and
results from the first 8 years. Osteoporos Int. 29:2335–2343.
2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Nishikawa A, Ishida T, Taketsuna M,
Yoshiki F and Enomoto H: Safety and effectiveness of daily
teriparatide in a prospective observational study in patients with
osteoporosis at high risk of fracture in Japan: Final report. Clin
Interv Aging. 11:913–925. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Smith J, Huvos AG, Chapman M, Rabbs C and
Spiro RH: Hyperparathyroidism associated with sarcoma of bone.
Skeletal Radiol. 26:107–112. 1997.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Betancourt M, Wirfel KL, Raymond AK, Yasko
AW, Lee J and Vassilopoulou-Sellin R: Osteosarcoma of bone in
apatient with primary hyperparathyroidism: A case report. J Bone
Miner Res. 18:163–166. 2003.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Jutte PC, Rosso R, de Paolis M, Errani C,
Pasini E, Campanacci L, Bacci G, Bertoni F and Mercuri M:
Osteosarcoma associated with hyperparathyroidism. Skeletal Radiol.
33:473–476. 2004.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Court-Brown CM and Caesar B: Epidemiology
of adult fractures: A review. Injury. 37:691–697. 2006.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Thorngren KG, Hommel A, Norrman PO,
Thorngren J and Wingstrand H: Epidemiology of femoral neck
fractures. Injury. 33 (Suppl 3):C1–C7. 2002.PubMed/NCBI View Article : Google Scholar
|
